
|Articles|December 1, 2001
New oral agent may improve painful IC symptoms
Shiga, Japan-The improvement of interstitial cystitis symptoms with a still-investigational oral agent correlates well with a reduction in bladder platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) expression, suggesting the agent's potential for treating symptoms in patients with nonulcerative IC.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
NDV-01 produces robust 9-month results in high-risk NMIBC
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
4
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
5


















